The genetic tumor background is an important determinant for heterogeneous MYCN‐amplified neuroblastoma

Amplification of MYCN is the signature genetic aberration of 20–25% of neuroblastoma and a stratifying marker associated with aggressive tumor behavior. The detection of heterogeneous MYCN amplification (hetMNA) poses a diagnostic dilemma due to the uncertainty of its relevance to tumor behavior. He...

詳細記述

保存先:
書誌詳細
出版年:Int J Cancer
主要な著者: Bogen, Dominik, Brunner, Clemens, Walder, Diana, Ziegler, Andrea, Abbasi, Reza, Ladenstein, Ruth L., Noguera, Rosa, Martinsson, Tommy, Amann, Gabriele, Schilling, Freimut H., Ussowicz, Marek, Benesch, Martin, Ambros, Peter F., Ambros, Inge M.
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2016
主題:
Tumor Markers and Signatures
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4949549/
https://ncbi.nlm.nih.gov/pubmed/26910568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.30050
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料